Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the ...

Donepezil increases the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. There is no evidence that donepezil alters the course of the underlying ...

Donepezil oral tablet is available as a brand-name drug and a generic drug. Brand name: Aricept. Donepezil comes in two oral tablet forms: tablet and disintegrating tablet (ODT). Donepezil oral tablet ...

March 7, 2012 — The cholinesterase inhibitor donepezil (Aricept, Pfizer), which is widely used to treat mild to moderate Alzheimer's disease (AD), also appears to be beneficial in patients with ...

Older patients prescribed donepezil had a higher risk for hospital admission for rhabdomyolysis than patients prescribed rivastigmine or galantamine, according to a population-based cohort study ...

The acetylcholinesterase inhibitor donepezil (Aricept) failed to improve chemotherapy-related cognitive impairment (CRCI) in breast cancer survivors, a placebo-controlled trial showed. After 24 weeks ...

(HealthDay News) – For patients with moderate-to-severe Alzheimer’s disease, continuation of treatment with donepezil is linked to significant cognitive benefits, according to a study published in the ...

BRIDGEWATER, N.J., January 23, 2025--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has ...

Actavis today announced the launch of Donepezil in some of Europe's biggest markets, immediately after the patents expired. The conventional tablets were launched in Germany, France, Italy, Spain, the ...